In conclusion, while LRRK2 and GBA1 mutations are both associated with a specific increase in basal forebrain volume at the asymptomatic stage, this increase persists at the symptomatic PD stage only in LRRK2 carriers and might be related to the slower rate of cognitive decline in these patients. The gene discussed is LRRK2; the disease is Parkinson disease.